RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of “Moderate Buy” by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $25.67.

A number of brokerages have issued reports on RAPT. Cantor Fitzgerald lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, February 20th. JPMorgan Chase & Co. reduced their target price on RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. Evercore ISI initiated coverage on RAPT Therapeutics in a research report on Friday, February 16th. They set an “outperform” rating for the company. Barclays decreased their target price on RAPT Therapeutics from $35.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, February 21st. Finally, Leerink Partnrs lowered shares of RAPT Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 21st.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $8.10 on Monday. The business’s 50-day moving average is $8.87 and its 200 day moving average is $15.50. RAPT Therapeutics has a 1 year low of $6.86 and a 1 year high of $27.35. The firm has a market capitalization of $281.88 million, a P/E ratio of -2.66 and a beta of 0.47.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.05. On average, analysts expect that RAPT Therapeutics will post -3.19 EPS for the current year.

Hedge Funds Weigh In On RAPT Therapeutics

Several institutional investors have recently made changes to their positions in RAPT. Exchange Traded Concepts LLC boosted its holdings in RAPT Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,190 shares of the company’s stock worth $179,000 after buying an additional 1,824 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of RAPT Therapeutics by 347.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock worth $99,000 after acquiring an additional 3,092 shares in the last quarter. Swiss National Bank grew its position in shares of RAPT Therapeutics by 9.6% during the 3rd quarter. Swiss National Bank now owns 49,100 shares of the company’s stock valued at $816,000 after acquiring an additional 4,300 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of RAPT Therapeutics in the 4th quarter valued at about $233,000. Finally, SG Americas Securities LLC acquired a new position in RAPT Therapeutics in the 4th quarter worth about $244,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.